Hostname: page-component-cd9895bd7-fscjk Total loading time: 0 Render date: 2024-12-19T07:23:03.521Z Has data issue: false hasContentIssue false
  • English
  • Français

The effect of memantine on sleep architecture and psychiatric symptoms in patients with Alzheimer’s disease

Published online by Cambridge University Press:  17 November 2015

Ichiro Ishikawa ,
Hideto Shinno ,
Nobuo Ando ,
Takahiro Mori  and
Yu Nakamura
Ichiro Ishikawa
Affiliation:
Department of Neuropsychiatry, Kagawa University School of Medicine, Miki, Kita, Kagawa, Japan
Hideto Shinno*
Affiliation:
Department of Neuropsychiatry, Kagawa University School of Medicine, Miki, Kita, Kagawa, Japan Department of Liaison Psychiatry, Kagawa University School of Medicine, Miki, Kita, Kagawa, Japan
Nobuo Ando
Affiliation:
Department of Neuropsychiatry, Kagawa University School of Medicine, Miki, Kita, Kagawa, Japan
Takahiro Mori
Affiliation:
Department of Neuropsychiatry, Kagawa University School of Medicine, Miki, Kita, Kagawa, Japan
Yu Nakamura
Affiliation:
Department of Neuropsychiatry, Kagawa University School of Medicine, Miki, Kita, Kagawa, Japan
*
Hideto Shinno, Department of Liaison Psychiatry, Kagawa University School of Medicine, 1750-1 Ikenobe, Miki, Kita, Kagawa 761-0793, Japan. Tel: +81 87 891 2167; Fax: +81 87 891 2168; E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective

Behavioural and psychological symptoms of dementia (BPSD) are commonly present in patients with Alzheimer’s disease (AD). Disturbed sleep quality is also observed in AD patients. However, the effects of memantine on sleep architecture have not been investigated. The purpose of this study was to investigate the effects of memantine on polysomnography (PSG) variables and BPSD.

Methods

In total, 12 patients with AD (mean age: 79.0±4.1 years old) were enrolled in this study. The following tests were performed: the Neuropsychiatric Inventory for the assessment of BPSD, the Mini-Mental State Examination (MMSE) for cognitive function, and PSG for evaluation of sleep architecture. After baseline examinations, patients were treated with memantine according to a standard prescription protocol. After being treated with 20 mg/day of memantine for 4 weeks, examinations were carried out again.

Results

All subjects completed the trial. The mean MMSE and NPI scores were 22.6±3.4 and 13.8±12.9, respectively. Treatment with memantine significantly decreased the NPI score (5.8±4.3, p<0.01). There were significant decreases in the scores of subscales for anxiety (p=0.04) and irritability/lability (p=0.04). PSG demonstrated a longer total sleep time (TST) (p<0.01), increases in sleep efficiency (p<0.01) and time spent in stage II (% TST, p=0.02), and decreases in nocturnal awakening (p<0.01), the periodic limb movement index (p<0.01), and time spent in stage I (% TST, p=0.02).

Conclusion

Memantine was effective for reducing fragmented sleep and improving BPSD, and was well tolerated.

Keywords

Alzheimer’s diseasebehavioural and psychological symptoms of dementia (BPSD)N-methyl-D-aspartateperiodic limb movementpolysomnography
Type
Original Articles
Information
Acta Neuropsychiatrica , Volume 28 , Issue 3 , June 2016 , pp. 157 - 164
Check for updates
Copyright
© Scandinavian College of Neuropsychopharmacology 2015 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Lee, PE, Gill, SS, Freedman, M, Bronskill, SE, Hillmer, MP, Rochon, PA. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ 2004;329:75.CrossRefGoogle ScholarPubMed
2. Schneider, LS, Tariot, PN, Dagerman, KS et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med 2006;355:1525–1538.Google Scholar
3. Paleacu, D, Barak, Y, Mirecky, I, Mazeh, D. Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer’s disease patients: a 6-week, double-blind, placebo-controlled study. Int J Geriatr Psychiatry 2008;23:393–400.Google Scholar
4. Food and Drug Administration. Deaths with antipsychotics in elderly patients with behavioral disturbances. FDA Public Health Advisory. Rockville, 2005.Google Scholar
5. Montplaisir, J, Petit, D, Lorrain, D, Gauthier, S, Nielsen, T. Sleep in Alzheimer’s disease: further considerations on the role of brainstem and forebrain cholinergic populations in sleep-wake mechanisms. Sleep 1995;18:145–148.Google Scholar
6. Bliwise, DL. Normal sleep and its variations. Normal Aging. In: Kryger M, Roth T, Dement W, editors. Principles and practice of sleep medicine, 5th edn. Philadelphia, PA: Elsevier Saunders, 2011. p. 27–41.Google Scholar
7. Petit, D, Montplaisir, J, Boeve, BF. Alzheimer’s disease and other dementias. In: Kryger M, Roth T, Dement W, editors. Principles and practice of sleep medicine, 5th edn. Philadelphia, PA: Elsevier Saunders, 2011. p. 1038–1047.Google Scholar
8. Montplaisir, J, Allen, RP, Walters, AS, Ferini-Strambi, L. Restless legs syndrome and periodic limb movements during sleep. In: Kryger M, Roth T, Dement W, editors. Principles and practice of sleep medicine, 5th edn. Philadelphia, PA: Elsevier Saunders, 2011. p. 1026–1037.Google Scholar
9. Prinz, PN, Peskind, ER, Vitaliano, PP et al. Changes in the sleep and waking EEGs of nondemented and demented elderly subjects. J Am Geriatr Soc 1982;30:86–93.Google Scholar
10. Wu, YH, Swaab, DF. The human pineal gland and melatonin in aging and Alzheimer’s disease. J Pineal Res 2005;38:145–152.Google Scholar
11. Jones, RW. A review comparing the safety and tolerability of memantine with the acetylcholinesterase inhibitors. Int J Geriatr Psychiatry 2010;25:547–553.Google Scholar
12. Paoletti, P, Neyton, J. NMDA receptor submits: function and pharmacology. Curr Opin Pharmacol 2007;7:39–47.Google Scholar
13. Traynelis, SF, Wollmuth, LP, Mcbain, CJ et al. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev 2010;62:405–496.Google Scholar
14. Ye, X, Carew, TJ. Small G protein signaling in neuronal plasticity and memory formation: the specific role of ras family proteins. Neuron 2010;68:340–361.Google Scholar
15. Kalia, LV, Kalia, SK, Salter, MW. NMDA receptors in clinical neurology: excitatory times ahead. Lancet Neurol 2008;7:742–755.Google Scholar
16. Ikonomidou, C, Bosch, F, Miksa, M et al. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science 1999;283:70–74.Google Scholar
17. Fiske, BK, Brunjes, PC. NMDA receptor regulation of cell death in the rat olfactory bulb. J Neurobiol 2001;47:223–232.Google Scholar
18. Yamada, K, Nabeshima, T. Changes in NMDA receptor/nitric oxide signaling pathway in the brain with aging. Microsc Res Tech 1998;43:68–74.Google Scholar
19. Butterfield, DA, Pocernich, CB. The glutamatergic system and Alzheimer’s disease: therapeutic implications. CNS Drugs 2003;17:641–652.Google Scholar
20. Li, S, Jin, M, Koeglsperger, T, Shepardson, NE, Shankar, GM, Selkoe, DJ. Soluble Aβ ologomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci 2011;31:6627–6638.Google Scholar
21. Wang, ZC, Zhao, J, Li, S. Dysregulation of synaptic and extrasynaptic N-methyl-D-aspartate receptors induced by amyloid–β. Neurosci Bull 2013;29:752–760.Google Scholar
22. Parsons, CG, Gruner, R, Rozental, J, Millar, J, Lodge, D. Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). Neuropharmacology 1993;32:1337–1350.Google Scholar
23. Scarpini, E, Scheltens, P, Feldman, H. Treatment of Alzheimer’s disease: current status and new perspectives. Lancet Neurol 2003;2:539–547.Google Scholar
24. Pallàs, M, Camins, A. Molecular and biochemical features in Alzheimer’s disease. Curr Pharm Des 2006;12:4389–4408.Google Scholar
25. Gardoni, F, Luca, Di. New targets for pharmacological intervention in the glutamatergic synapse. Eur J Pharmacol 2006;545:2–10.Google Scholar
26. More, L, Gravius, A, Nagel, J, Valastro, B, Greco, S, Danysz, W. Therapeutically relevant plasma concentration of memantine produce significant L-N-methyl-D-aspartate receptor occupation and do not impair learning in rats. Behav Pharmacol 2008;19:724–734.Google Scholar
27. Gauthier, S, Wirth, Y, Möbius, HJ. Effects of memantine on behavioural symptoms in Alzheimer’s disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomized, controlled studies. Int J Geriatr Psychiatry 2005;20:459–464.Google Scholar
28. Folstein, MF, Folstein, SE, Mchugh, PR. ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.Google Scholar
29. Morris, JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412–2414.Google Scholar
30. Cummings, JL, Mega, M, Gray, K, Rosenberg-Thompson, S, Carusi, DA, Gornbein, J. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308–2314.Google Scholar
31. Soldatos, CR. The assessment of insomnia: rationale for a new scale based on ICD-10 principles. In: Szelenberger W, Kukwa A, editors. Sleep: physiology and pathology. Warszawa: Elma Books, 1995. p. 119–131.Google Scholar
32. Mckhann, G, Drachman, D, Folstein, M, Katzman, R, Price, D, Stadlan, EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer’s disease. Neurology 1984;34:939–944.CrossRefGoogle ScholarPubMed
33. Rechtschaffen, A, Kales, A. A manual of standardized terminology, techniques, and scoring system for sleep states of human subjects USPHS Publication No. 204. Washington, DC: US Government Printing Office, 1968.Google Scholar
34. Lapierre, O, Montplaisir, J. Polysomnographic features of REM sleep behavior disorder: development of a scoring method. Neurology 1992;42:1371–1374.Google Scholar
35. Iber, C, Ancoli-Israel, S, Chesson, A, Quan, SF, American Academy of Sleep Medicine. The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications, 1st edn. Illinois: American Academy of Sleep Medicine, 2007.Google Scholar
36. American Academy of Sleep Medicine. ICSD-2 – international classification of sleep disorders: diagnostic and coding manual, 2nd edn. Illinois: American Academy of Sleep Medicine, 2005.Google Scholar
37. Reisberg, B, Doody, R, Stoffler, A, Schmitt, F, Ferris, S, Mobius, HJ, Memantine Study Group. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med 2003;348:1333–1341.Google Scholar
38. Nakamura, Y, Kitamura, S, Homma, A, Shiosakai, K, Matsui, D. Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer’s disease: results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan. Expert Opin Pharmacother 2014;15:913–925.Google Scholar
39. Molino, I, Colucci, L, Fasanaro, AM, Traini, E, Amenta, F Efficacy of memantine, donepezil, or their association in moderate-severe Alzheimer’s disease: a review of clinical trials. ScientificWorldJournal 2013;2013:925702 doi: 10.1155/2013/925702.Google Scholar
40. Fox, C, Crugel, M, Maidment, I et al. Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double-blind placebo controlled trial. PLoS One 2012;7:e35185 doi: 10.1371/journal.pone.0035185.CrossRefGoogle ScholarPubMed
41. Rainer, M, Wuschitz, A, Jagsch, C, Erb, C, Chirikdjian, JJ, Mucke, HA. Memantine in moderate to severe Alzheimer’s disease: an observational post-marketing study. J Neural Transm 2011;118:1255–1259.CrossRefGoogle ScholarPubMed
42. Montplaisir, J, Michaud, M, Denesle, R, Gosselin, A. Periodic leg movements are not more prevalent in insomnia or hypersomnia but are specially associated with sleep disorders involving a dopaminergic impairment. Sleep Med 2000;1:163–167.Google Scholar
43. Jama, L, Hirvonen, K, Partinen, M et al. A dose-ranging study of pramipexole for the symptomatic treatment of restless legs syndrome: polysomnographic evaluation of periodic leg movements and sleep disturbance. Sleep Med 2009;10:630–636.Google Scholar
44. Staedt, J, Stoppe, G, Kogler, A et al. Single photon emission tomography (SPET) imaging of dopamine D2 receptors in the course of dopamine replacement therapy in patients with nocturnal myoclonus syndrome (NMS). J Neural Transm Gen Sect 1995;99:187–193.CrossRefGoogle ScholarPubMed
45. Wang, M, Wong, AH, Liu, F. Interactions between NMDA and dopamine receptors: a potential therapeutic target. Brain Res 2012;1476:154–163.Google Scholar
46. Spanagel, R, Eilbacher, B, Wilke, R. Memantine-induced dopamine release in the prefrontal cortex and striatum of the rat – a pharmacokinetic microdialysis study. Eur J Pharmacol 1994;262:21–26.Google Scholar